Nxera earns $15 million as Neurocrine advances schizophrenia drug

3 June 2025

Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after the first patient was dosed in a Phase III study of NBI-1117568, a potential new treatment for schizophrenia.

The global trial will enroll about 280 adults with acute symptom relapse. Its main goal is to measure changes on the Positive and Negative Syndrome Scale, with a secondary focus on clinician-rated severity improvements.

While the drug has not yet generated revenue, forecasts suggest it could bring in $120 million annually in the USA if approved. The two companies are hoping to fill longstanding treatment gaps in a field where roughly one in three patients do not respond well to current therapies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical